Microbot Medical Makes Strategic Move with $13 Million Offering
Microbot Medical Inc. (NASDAQ: MBOT) has recently taken an important step to elevate its operations by entering into definitive agreements to sell 6,103,289 shares of its common stock at a price of $2.13 per share. This registered direct offering, priced at-the-market under Nasdaq rules, underscores the company's commitment to advancing its innovative technologies.
Details of the Offering
In this financial maneuver, alongside the registered direct offering, the company is also executing a private placement where it will issue short-term series I preferred investment options. These options will allow for the purchase of up to 12,206,578 shares of common stock, mirroring the share price of $2.13 each. Notably, these investment options will be exercisable for two years, beginning on a date contingent upon stockholder approval of the required increase in the company’s authorized shares.
Expected Closing and Proceeds Use
The closing of this investment initiative is anticipated to occur shortly after the agreements, pending customary closing conditions. The gross proceeds from both offerings are expected to total approximately $13 million, allowing the company to further its strategic objectives before accounting for any fees or expenses associated with this endeavor.
Strategic Goals for the Proceeds
The net funds raised will be pivotal for Microbot Medical as they focus on the continued development and commercialization of their flagship LIBERTY Robotic System. This innovative technology captures the company’s vision to enhance patient care by utilizing advanced robotic capabilities.
Innovative Solutions from Microbot Medical
Microbot Medical is at the forefront of medical technology, dedicated to providing groundbreaking solutions for healthcare providers and patients. The unique LIBERTY system is the first fully disposable endovascular robotic system that makes advanced robotic assistance more accessible. This revolutionary approach aims at overcoming traditional barriers to high-quality medical interventions.
Plans for Future Developments
The company is aggressively pursuing the commercialization pathway and plans to expand upon its already impressive intellectual property portfolio. With the proceeds from the recent offering, Microbot will also focus on regulatory activities necessary for bringing its innovative products to market.
Commitment to Compliance and Transparency
Microbot Medical’s registered direct offering is made available through a shelf registration statement on Form S-3, filed with the Securities and Exchange Commission (SEC). This underlines the company’s adherence to all financial regulations and its commitment to transparency in its operations. Moreover, the short-term series I preferred investment options are being issued in compliance with Section 4(a)(2) of the Securities Act, ensuring responsible and proper execution.
About Microbot Medical
Microbot Medical is a clinical-stage organization poised to revolutionize medical technology. Its mission to improve medical care through robotic solutions is evident in its continual development of the LIBERTY system. As the company expands its reach, its focus remains on patient welfare and technological advancement.
Further Information
For those wanting to learn more, Microbot Medical provides additional insights about its technologies and initiatives on its official website, a resource where stakeholders can stay informed about future developments and offerings.
Frequently Asked Questions
What does the $13 million offering entail?
The offering includes the sale of common stock and short-term investment options aimed at generating funds for company development and commercialization efforts.
How will Microbot Medical utilize the proceeds from this offering?
The funds will primarily support the commercialization of the LIBERTY Robotic System and assist in regulatory processes and expansion of their IP applications.
What is the significance of the LIBERTY Robotic System?
The LIBERTY Robotic System is the world's first fully disposable endovascular robotic system, which aims to enhance access and quality of care in medical procedures.
Who is managing the offerings for Microbot Medical?
H.C. Wainwright & Co. is acting as the exclusive placement agent for the registered direct offering and private placement.
Are the investment options registered?
No, the short-term series I preferred investment options and the shares of common stock underlying them have not been registered under the Securities Act or applicable state laws.
